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OncologyA B S T R A C T
Diabetes and cancer frequently coexist in the same subject, often with relevant clinical
effects on the management and prognosis of the comorbid patient. The existing guidelines,
however, do not appropriately address many clinical issues in this setting. Although collab-
oration between diabetologists and oncologists should play an important role in achieving
appropriate levels of care, close coordination or agreement between these specialists is sel-
dom offered. There is an urgent need for greater interdisciplinary integration between all
specialists involved in this setting, for a shared approach ensuring that organisational silos
are overcome. To this end, the Italian Associations of Medical Diabetologists (AMD) and the
Italian Association of Medical Oncology (AIOM) recently established a dedicated Working
Group on ‘Diabetes and Cancer’. The working group outlined a diagnostic and therapeutic
clinical pathway dedicated to hospitalised patients with diabetes and cancer. In this article,
we describe the Italian proposal including some suggested measures to assess, monitortes: A pro-
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from both areas, as well as to ensure discharge planning and continuity of care from the
hospital to the territory.
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Diabetes and cancer are quite common diseases in Western
countries, so it is not rare for a patient to present with both
conditions at the same time. The general aging of the popula-
tion also helps to explain the association between diabetes
and oncological diseases, as both conditions become more
common as age increases. It has been estimated that between
8% and 18% of oncology patients also have diabetes [1–6].
The presence of diabetes, in addition to significantly
increasing the risk of cancer, has an unfavourable effect on
the prognosis of many tumours. First of all, patients with dia-
betes seem to have their cancer diagnosis later than the gen-
eral population (due to underuse of screening tests or due to
less attention by those caring for them); also, these patients
seem to undergo less aggressive treatments for cancer (for
example, due to the presence of renal or neuropathic compli-
cations), which would expose them to worse responses to
treatment. Among other causes, experts cite the greater
prevalence of infections, increased post-surgical mortality,
heightened toxicity of treatments or elevated aggressiveness
of the neoplastic cells when proliferating in an environment
of chronic hyperglycaemia/hyperinsulinaemia. Patients who
have had diabetes for a longer time and are undergoing insu-
lin treatments have an especially low cumulative survival
rate, independent of gender and for many types of cancers [7].
Thus, diabetes management is often of crucial importance
in cancer patients. Despite this evidence, there is little data on
the clinical approach to take with cancer patients who have
an altered glucose metabolism [8–16]. Collaboration and inter-
action between the different specialists involved, therefore,
play a key role in achieving appropriate levels of care. Very
often, in fact, diabetologists and oncologists find themselves
working in an uncoordinated or contradictory manner, result-
ing in duplicated procedures, inappropriate admissions,
delays in access to services for diabetes, improper work with
less than optimal service, lack of motivation and loss of pro-
fessionalism on both sides [17].
Realizing the need for health care professionals to improve
the quality of care and assistance provided to people with dia-
betes who have oncological diseases, the Italian Association
of Medical Diabetologists (AMD) and the Italian Association
of Medical Oncology (AIOM) recently established a dedicated
working group on ‘Diabetes and Cancer’, counting among its
goals that of improving the quality of services offered to the
comorbid patient with diabetes and cancer, to offer a staff
response to the fragmentation of care, and to encourage inte-
gration, with mutual respect for each other’s roles, among
diabetologists and oncologists in order to improve clinicale, D. Cristiano Corsi et al.
search and Clinical Practiceappropriateness and efficacy along with an optimisation of
resources [18].
Between October 2014 and April 2015, the working group
promoted and carried out a survey that involved 252 Italian
physicians (diabetologists, oncologists, and palliativists). This
survey provided interesting data about the critical care issues
in managing cancer patients with alterations to their glucose
metabolism [19]. For example, it found that:
- even though the presence of diabetes (or diabetic compli-
cations) worsens the outcome of cancer treatments, coun-
selling or intervention by a diabetologist was only required
for less than two-thirds of hospitalised patients.
- For subjects with a life expectancy of months, 80% of dia-
betologists considered an overly stringent blood glucose
target (120–250 mg/dL) to be optimal, whereas oncologists
were more likely to consider a more relaxed range (180–
360 mg/dL) for patients with a shorter life expectancy.
- One participant out of 3 indicated 1–4 measurements/day
as the most appropriate frequency for blood glucose mon-
itoring, including in a palliative setting.
The data collected in the survey confirmed, on the one
hand, the need for greater interdisciplinary integration to
achieve a shared approach aimed at overcoming organisa-
tional issues of ‘compartmentalisation’; and on the other
hand, the need to ensure nationally identical standards of
quality and appropriateness in managing this type of patient.
Based on these observations, the working group outlined
an integrated diagnostic and therapeutic clinical pathway
dedicated to the management of cancer patients with dia-
betes. In this position paper, we describe the Italian proposal
including some suggested measures to assess, monitor and
improve blood glucose control in the hospital setting, to inte-
grate the multidisciplinary team involved in caring for this
category of patient, as well as to ensure discharge planning
and continuity of care from the hospital to the territory.
2. Materials and methods
Working with the survey results, the experience gained in the
Italian Piedmont and Valle d’Aosta regions (where a shared
clinical pathway has been used for years in managing cancer
patients with diabetes during a hospital stay and then after
discharge) [20], the Italian guidelines for diabetes manage-
ment [14] and the few international recommendations, AMD
and AIOM formally prepared a document that was validated
and approved in its final form in March 2018. This article con-
veys the essentials of that document., An integrated care pathway for cancer patients with diabetes: A pro-
, https://doi.org/10.1016/j.diabres.2019.04.036
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3.1. Aim of the clinical pathway
The purpose of this process is:
- to provide an assessment of the oncology patient with an
altered glucose metabolism during the hospital stay (hos-
pital ward, day hospital, consulting office);
- to establish an optimal, personalised plan for diabetes care
in relation to the overall situation and the prognosis;
- to reduce the risks related to hyper- or hypoglycaemia dur-
ing hospitalisation and the risks related to adverse events
from the diabetes treatments, and to ensure the best qual-
ity of life possible;
- to make sure there is communication between the various
professionals involved, as well as continuity of care upon
discharge from the hospital.
Patients with diabetes become involved in an oncology set-
ting under two circumstances: through the relevant outpa-
tient clinic or during a stay in a specific hospital setting.
In an outpatient setting, the patient may be newly diag-
nosed with diabetes, often concurrent with an acute meta-
bolic decompensation, especially due to supportive
treatments with steroids, or during check-up examinations
with the oncologist. In this context, it is important to be prop-
erly aware of the need to recognize patients at risk for devel-
oping diabetes, considering risk factors like obesity and
family history of diabetes, and to pay attention to altered fast-
ing blood glucose, for prompt recognition of the disease and
to prevent acute decompensation events. In the latter circum-
stance, which it is preferable to prevent, the diabetologist
consultation assumes an urgent nature and thus care path-
ways must be prepared that are mutually agreed upon with
the hospital’s diabetes clinical team.
If a diagnosis of non-decompensated diabetes takes place
during an outpatient examination or at an oncology day hos-
pital, control (even if temporary) must be taken by the dia-
betes team to ensure the closest consultations with the
oncology staff; this possibility should also be considered for
patients with previously diagnosed diabetes that is managed
at another diabetes centre and agreed upon with that centre
as well; in any case, it is essential to implement an expanded
diabetes team that includes the oncologist due to the special
circumstances surrounding the care of a oncological patient
with diabetes.
Indeed, the diabetologist must re-establish the new goals
for care and metabolic compensation, assessing the clinical
situation, the oncological treatment plan and the prognosis,
while remaining in close contact with the oncologist and
the caregiver.
Often, too, a significant educational effort is required at
the start of insulin treatment because of the need for
increased compatibility with the potential alterations the
oncology treatments induce in hepatic and/or renal function-
ing and the need for greater flexibility in monitoring changesPlease cite this article as: M. Gallo, G. Clemente, D. Cristiano Corsi et al.
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portive steroid treatment.
This involves not only education on insulin therapy and
self-monitoring of blood glucose at home, but also refining
the therapy and the possibility of using different insulin
administration strategies depending on changes in blood
glucose levels related to steroid dosage, its half-life, the tim-
ing and splitting up the steroid treatment, or changes in the
timing of the administration of insulin therapy depending
on changed dietary needs and the ability to eat. Insulin
plans and self-monitoring plans may include increased elas-
ticity, becoming more intensive along with the cycles of
oncological treatment. The educational effort is thus aimed
at reaching greater empowerment of the patient through
greater compliance and awareness of managing this
condition.
For patients with a good prognosis, compliance with blood
glucose targets and blood glucose compensation, as agreed on
with the patient, should be strictly maintained. For patients
with a short life expectancy, however, the priorities must
focus on:
(1) different nutritional requirements,
(2) avoiding hypoglycaemia,
(3) avoiding the consequences related to hyperglycaemia
(dehydration, infections, etc.),
(4) preserving quality of life by simplifying the plans for
blood glucose self-monitoring and treatment.
For a patient with diabetes (whether previously known or
newly diagnosed) admitted to an oncology ward, the acti-
vated hospital diabetes team will carry out its own care activ-
ities for the patient in the hospital, though the proper details
of managing diabetes during the course of cancer remain
valid. This activation, as in any hospital setting, is fully
achieved by establishing the insulin treatment, formulating
the dose correction plan during administration, avoiding
‘sliding scale’ insulin administration alone, preparing and
sharing with the medical and nursing staff the protocols for
the administration of insulin in the critical patient who can-
not, must not or does not know how to feed him- or herself,
preventing the clinical risk related to hypoglycaemia during
hospitalisation, establishing when and how to begin insulin
treatment concurrent with artificial, parenteral or enteral
feeling, and finally a protected hospital discharge to the pri-
mary care physician with delivery of medications and ser-
vices, instructions for insulin treatment and home self-
monitoring of blood glucose, and the prescription of medica-
tions and devices.
It is essential for the diabetologist to take charge far
enough in advance of discharge to educate the patient and
the caregiver, as well as contacting the diabetes team that is
treating or will treat the patient thereafter, where the
expanded diabetes team will include the oncologist and clo-
sely involve the caregiver, and in which the diabetologist
plays a central role due to the special aspects of managing
the oncological diabetes patient, for urgent metabolic proce-, An integrated care pathway for cancer patients with diabetes: A pro-
e, https://doi.org/10.1016/j.diabres.2019.04.036
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tion of the diagnostic/therapeutic intra-hospital protocols,
and finally to ensure continuity of care between the hospital
and the territorial health care provider.
3.2. Description of the input
Oncology patient with already known diabetes, or who devel-
ops changes in glycaemic homeostasis due to cancer
treatments.
3.3. Description of the output
- Comprehensive organisation of the oncology patient with
diabetes, considering the patient’s medical history, overall
clinical condition, nutrition, and the prognostic and thera-
peutic perspectives.
- Training (of the patient and/or the caregiver) on self-
monitoring of blood glucose (if needed).
- Training (of the patient and/or the caregiver) in self-
management of the diabetes treatment and any episodes
of decompensation (hypo- or hyperglycaemia).
- Optimal blood glucose control based on the personalised
target (based on the stage of the cancer).
- ‘Protected’ discharge that ensures, when necessary, conti-
nuity of care with:
 The local diabetologist.
 The primary care physician.
 The hospice, home care team or caregiver.
3.4. Methodology
We propose the implementation of a facility-wide, multidisci-
plinary team (oncologist, haemato-oncologist, nutritionist,
palliativist, radiation therapist, nursing staff) that is coordi-
nated by the diabetologist, who receives the formal assign-
ment from the hospital Healthcare Management to create a
clinical pathway, and who is supported in writing it by the
Quality Office.
The multidisciplinary group will draw up specific Respon-
sibility Matrices based on the features of the facility in ques-
tion and the available resources, in order to identify the
health care professionals responsible for performing specific
functions in diabetes assistance to the oncology patient dur-
ing the hospital stay or during the outpatient visit. Tables 1
and 2 are examples of such matrices.
Through the multidisciplinary team identified, each centre
must also provide specific operational instructions for the
management of the various critical issues that may arise in
each assistance setting (e.g., plans for varying insulin treat-
ment based on blood glucose values; plans for calculating cor-
rective doses of insulin; instructions for managing acute
blood glucose decompensation in the oncology day hospital
and the hospital wards; instructions for managing hypogly-
caemia, etc.).
Following the drafting, the document must be shared with
the personnel involved, and there must be dedicated training
of the workers (Training Office). It will also be necessary toPlease cite this article as: M. Gallo, G. Clemente, D. Cristiano Corsi et al.
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clinical and organisational audit.
3.5. Control points and indicators
Different control points and indicators can be identified for
assessing the activities performed through the implementa-
tion of the clinical pathway. Among the possible control
points, the AMD-AIOM Working Group identified the
following:
- Number of cancer patients with diabetes who have limita-
tions on cancer treatments related to the presence of
diabetes;
- Number of days between the request for a diabetologist
consultation and when it occurs;
- Number of days between the request and when the team
performs the assessment for protected discharge;
- Cancer patients with cancer with average blood glucose
levels on target (individualised based on prognosis);
- Number of hypoglycaemic episodes (<70 mg/dl);
- Number of episodes of blood glucose decompensation
(>400 mg/dl);
- Number of oncological patients with diabetes trained in
self-monitoring of blood glucose;
- Impact on the patient’s quality of life caused by the dia-
betologist taking charge.
We have identified some of the possible specific indicators
(descriptive, process, intermediate outcome and final out-
come indicators) that can be used in analysing the efficacy
of the clinical pathway, which are listed in Tables 3–6.
4. Conclusions
Changes in glucose metabolism can be one of the metabolic
complications of cancer and of the most commonly used can-
cer treatments. Despite the observed frequency of the two
associated conditions, there is relatively little data or experts
recommendations on which clinical approach to use in the
oncology patient with an altered glucose metabolism. There-
fore, clinical management depends largely on local habits,
skills and practices, often in the absence of appropriate coor-
dination with oncologists, haemato-oncologists, nutritionists,
palliativists, and other professionals involved in caring for
this category of patient.
The available data from surveys conducted in Italy and
other countries document, on the one hand, the need for
better interdisciplinary integration among the various
healthcare providers involved in managing patients simul-
taneously suffering from diabetes and cancer, to achieve a
shared approach that ensures overcoming organisational
‘compartmentalisation’, in terms of continued improvement
and integration among the various professional experts.
The data also show the need for all the diabetologists in
a given geographic area to ensure identical quality stan-
dards and appropriateness in managing this situation.
The formation of a joint working group, one aspect of the
collaboration between two of the major Italian scientific
associations dealing with, respectively, diabetes treatment, An integrated care pathway for cancer patients with diabetes: A pro-
, https://doi.org/10.1016/j.diabres.2019.04.036
Table 1 – Sample matrix of responsibilities for diabetic care of the inpatient or hospitalized oncology patient.
Activities Functions
What to do Actions to take Diab/
Endo
Diab/Endo PN Ward Oncol/
Doctor
Ward PN Other
Preliminary assessment of the oncology
patient’s metabolic profile, also depending on
the clinical characteristics of the cancer
condition and the overall outlook
Diabetes consultation with medical
history and targeted assessment:
performance status, nutrition, cancer
treatments and supportive care,
prognosis, needs for self-monitoring
services and training for self-
monitoring and insulin treatment,
caregiver availability, care setting
R I I A Caregiver (A)
Setting blood glucose goals Assessment of prognosis, general
condition, caregiver availability
R A I A Caregiver (A)
Establishment of diabetes treatment and blood
glucose monitoring plan
Establishment of personalised
treatment, specific protocol application
R A I I Caregiver (A)
Creation of a nutritional programme Nutritional history
Educational session, diet prescription
I A I A Dietitian (R), caregiver (A)
Management of acute metabolic complications
(eg, diabetic ketoacidosis and hyperglycemic
hyperosmolar state)
Protocol application I – R I
Assessment of treatment needs at discharge
(training, exemptions, services)
Observation and conversation with
patient and/or caregiver, assessment of
SMBG management ability and
treatment
I R A I
Issuance of documentation for exemption
document
Filling out forms R A A A GP (A), caregiver (A)
Issuance of documentation for provision of
services (glucose meter, strips, lances, needles,
etc.)
Filling out forms R A A A GP (A), caregiver (A)
Treatment education, SMBG Procedure personalised based on needs,
SMBG training, written instructions
I R A A* GP (A), caregiver (I)
Provision of services and medications Direct provision for the first days of
post-discharge treatment
A I A R** Hosp. pharmacist (I), GP
(A), caregiver (A)
Assessment of treatment and management of
diabetes after discharge
Diabetes consultation to establish home
diabetes treatment
R I I A Territorial diab/endo (A/I)
Treatment instructions for discharge Conversation and detailed discharge
letter
A R A GP (A), caregiver (A),
territorial diab/endo (A),
hospice personnel (A)
Scheduling a diabetes follow-up Diary, contact with GP and territorial
diab/endo (date, place and method of
access to post-discharge diabetes
monitoring)
R A I A GP (A), caregiver (A),
territorial diab/endo (I)
R = Responsible; I = Involved; A = Advised.
Diab/Endo = Diabetologist/Endocrinologist; DH = Day Hospital; GP = General Practitioner; Oncol = Oncologist; PN = Professional Nurse; SMBG = Self-Monitoring of Blood Glucose.
* In some hospital wards, this may be performed by the ward nurses (if appropriately trained).
** In some hospital wards, this is performed by the nurses on the diabetes team.
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Table 2 – Sample matrix of responsibilities for diabetes care for the oncology patient in an oncological outpatient/day hospital setting.
Activities Functions
What to do How to act Diab/Endo DH/Outpatient Oncol/Doctor DH/Outpatient PN Diab/Endo PN Other
Preliminary assessment of the
oncology patient’s metabolic
profile, also based on the clinical
characteristics of the cancer
condition and the overall
outlook
Diabetes consultation with
medical history and targeted
assessment: performance
status, nutrition, cancer
treatments and supportive care,
prognosis, needs for self-
monitoring services and training
for any self-monitoring and
insulin treatment, caregiver
availability, care setting
R I A A
For a new diagnosis of diabetes
and/or hyperglycaemia
Targeted medical history, blood
and/or plasma glucose added to
vital signs; HbA1c if indicated
I R I
Setting blood glucose goals Assessment of prognosis,
general condition, caregiver
availability
R I A A Caregiver (A)
Establishment of diabetes
treatment and blood glucose
monitoring plan
Establishment of personalised
treatment, specific protocol
application
R I A I Caregiver (A)
Creation of a nutritional plan Nutritional history
Educational session, diet
prescription
I I A A Dietitian (R), caregiver (A)
Assessment of treatment needs
(education, exemptions,
services)
Observation and conversation
with patient and/or caregiver,
assessment of SMBG
management ability and
treatment
I – A R Caregiver (I)
Treatment education Procedure personalised based on
needs, written instructions
A A A R GP (A), caregiver (A)
Education on prevention and
management of hypoglycaemia
and hyperglycaemia
Treatment education, provide
protocols
I A I R GP (A), caregiver (A)
Exemption document Filling out forms R A A A GP (A), caregiver (A)
Prescription for services Filling out forms R A A A GP (A), caregiver (A)
Provision of services and
medications
Direct supply for the first days of
treatment
I A A R GP (A), caregiver (A)
Scheduling a diabetes follow-up Diary, contact with GP and
territorial diab/endo
R A A I GP (A), caregiver (A),
territorial diab/endo (I)
Provision of Diab/Endo address
in case of need
Telephone, email, fax A A A R GP (A)
Management of acute metabolic
complications (eg, diabetic
ketoacidosis and hyperglycemic
hyperosmolar state)
Application of joint
management protocols
I (R)* I R* A
R = Responsible; I = Involved; A = Advised.
Diab/Endo = Diabetologist/Endocrinologist; DH = Day Hospital; GP = General Practitioner; Oncol = Oncologist; PN = Professional Nurse; SMBG = self-monitoring of blood glucose
* The application of shared management protocols is the oncologist’s responsibility; the diabetologist is responsible if no protocols exist.
6
d
ia
b
e
t
e
s
r
e
s
e
a
r
c
h
a
n
d
c
l
in
ic
a
l
p
r
a
c
t
ic
e
x
x
x
(x
x
x
x
)
x
x
x
P
lease
cite
th
is
article
as:
M
.
G
allo
,
G
.
C
lem
en
te,
D
.
C
ristian
o
C
o
rsi
et
al.,
A
n
in
tegrated
care
p
ath
w
ay
fo
r
can
cer
p
atien
ts
w
ith
d
iab
etes:
A
p
ro
-
p
o
sal
fro
m
th
e
Italian
exp
erien
ce,
D
iab
etes
R
esearch
an
d
C
lin
ical
P
ractice,
h
ttp
s://d
o
i.o
rg/10.1016/j.d
iab
res.2019.04.036
Table 3 – Specific descriptive indicators.
Number of cancer patients with diabetes, out of total patients with diabetes followed-up
Number of cancer patients newly diagnosed with diabetes during outpatient or day hospital oncology visit, out of total visits
performed
Number of cancer patients with previously known diabetes referred to an outpatient or day hospital oncology visit, sent for a
consultation with a diabetologist, out of total patients with diabetes making an oncology visit
Number of hospital consultations performed for cancer patients with diabetes, out of total consultations performed by the
Diabetology/Endocrinology Unit (or out of the hospital’s total consultations for diabetes)
Number of cancer patients with diabetes with acute hyperglycaemia assessed within 2 working days of the request for a visit
Number of consultations for cancer patients performed by the diabetes team within 2 working days from the request for a
consultation
Number of requests for consultation by the diabetes team that were performed more than 48 h before discharge, out of total
requests
Cases of secondary diabetes, out of total patients with diabetes followed-up
Distribution of cancer patients with diabetes based on estimated life expectancy
Number of patients with acute hyperglycaemia due to failure to apply the pre-established protocol
Table 4 – Specific process indicators.
Number of cancer patients with diabetes trained in blood glucose monitoring* out of total oncological subjects with diabetes
followed-up
Number of cancer patients with diabetes provided with a plan for blood glucose monitoring who correctly perform the blood
glucose monitoring, out of total oncological subjects with diabetes followed-up
Number of cancer patients trained in self-management of insulin therapy, out of total oncological subjects with diabetes
treated with insulin followed-up
Number of cancer patients with diabetes provided with an algorithm for self-titrating short-acting insulin dose, out of total
oncological subjects with diabetes treated with insulin followed-up
Number of cancer patients with diabetes treated with insulin, out of total subjects with diabetes followed-up
Number of cancer patients with diabetes treated with oral antidiabetics, out of total subjects with diabetes followed-up
Average length of diabetes/oncology follow-up
* Self-monitoring or monitoring performed by caregiver.
Table 5 – Specific intermediate outcome indicators.
Cancer patients with diabetes with average blood glucose on target (individualised based on prognosis), out of total subjects
with diabetes followed-up
Cancer patients with diabetes with repeated (>10) episodes of blood glucose >360 mg/dl in the last 3 months of life
Cancer patients with diabetes with severe hypoglycaemia in the last 3 months of life, out of total oncological subjects with
diabetes followed-up
Cancer patients with diabetes with <2–3 blood glucose checks per day in the last 3 months of life, out of total oncological
subjects with diabetes followed-up
Table 6 – Specific final outcome indicators.
Cancer patients with diabetes with repeated episodes (>10) of symptomatic hyperglycaemia, out of total patients with
diabetes followed-up
Cancer patients with diabetes with repeated (>5) episodes of severe hypoglycaemia in the last 3 months of life, out of total
patients with diabetes followed-up
Cancer patients with diabetes without dietary restrictions due to diabetes, out of total patients with diabetes followed-up
Cancer patients with diabetes whose quality of life did not worsen significantly due to diabetes, out of total cancer patients
with diabetes followed-up
Number of visits to the Emergency Room due to hypoglycaemia or acute hyperglycaemia
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e x x x ( x x x x ) x x x 7(AMD) and oncology treatment (AIOM), had as one of its goals
to provide a scientific, clinical and operational point of refer-
ence for this specific field. The recently developed integrated
management pathway for the oncological patient withPlease cite this article as: M. Gallo, G. Clemente, D. Cristiano Corsi et al.
posal from the Italian experience, Diabetes Research and Clinical Practicdiabetes, dedicated to inpatients and outpatients alike, is
intended as a useful tool in overcoming local health dispari-
ties and in sharing standards for essential assistance among
different Italian centres., An integrated care pathway for cancer patients with diabetes: A pro-
e, https://doi.org/10.1016/j.diabres.2019.04.036
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